{
  "first_published_at": "2009-06-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088105", 
  "title": "Erlotinib: new safety information", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 253, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Erlotinib: new safety information</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Erlotinib (Tarceva&#9660;) is a treatment for patients with locally advanced or metastatic non-small-cell lung cancer, and for patients with metastatic pancreatic cancer (in combination with gemcitabine). As part of continued intensive monitoring of this medicine, new safety information is available-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p><strong>Erlotinib</strong> (Tarceva&#9660;) is a treatment for patients with locally advanced or metastatic non-small-cell lung cancer, and for patients with metastatic pancreatic cancer (in combination with gemcitabine).</p><p>As part of continued intensive monitoring of this medicine, new safety information is available about the following risks:</p><ul>\r\n\t\t\t<li><strong>Gastrointestinal perforation</strong>: there have been reports of gastrointestinal perforation, and patients are at increased risk. Those who are receiving concomitant antiangiogenic agents, corticosteroids, non-steroidal anti-inflammatory drugs, or taxane-based chemotherapy, or who have a history of peptic ulceration or diverticular disease, are at increased risk. Erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li><strong>Bullous and exfoliative skin disorders</strong>: bullous, blistering, and exfoliative skin conditions have been reported, including very rare cases suggestive of Stevens-Johnson syndrome or toxic epidermal necrolysis, some of which were fatal. Erlotinib should be interrupted or discontinued if a patient develops severe bullous, blistering, or exfoliating conditions<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li><strong>Ocular disorders</strong>: very rare cases of corneal perforation or ulceration have been reported during use. Other ocular disorders including abnormal eyelash growth, keratoconjunctivitis sicca, or keratitis have been observed, which are risk factors for corneal perforation or ulceration. Erlotinib should be interrupted or discontinued if patients present with acute or worsening ocular disorders such as eye pain</li></ul><p>Please continue to report suspected adverse reactions to erlotinib on a <a href=\"http://www.yellowcard.gov.uk\" target=\"_blank\">Yellow Card</a></p><p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON049041\" title=\"Information sent to healthcare professionals in May 2009 about the safety of medicines\">Information sent to healthcare professionals in May 2009 about the safety of medicines</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update June 2009, vol 2 issue 11: 11b.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p><strong>Erlotinib</strong> (Tarceva&#9660;) is a treatment for patients with locally advanced or metastatic non-small-cell lung cancer, and for patients with metastatic pancreatic cancer (in combination with gemcitabine).</p><p>As part of continued intensive monitoring of this medicine, new safety information is available about the following risks:</p><ul>\r\n\t\t\t<li><strong>Gastrointestinal perforation</strong>: there have been reports of gastrointestinal perforation, and patients are at increased risk. Those who are receiving concomitant antiangiogenic agents, corticosteroids, non-steroidal anti-inflammatory drugs, or taxane-based chemotherapy, or who have a history of peptic ulceration or diverticular disease, are at increased risk. Erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li><strong>Bullous and exfoliative skin disorders</strong>: bullous, blistering, and exfoliative skin conditions have been reported, including very rare cases suggestive of Stevens-Johnson syndrome or toxic epidermal necrolysis, some of which were fatal. Erlotinib should be interrupted or discontinued if a patient develops severe bullous, blistering, or exfoliating conditions<br>\r\n\t\t\t\t<br></li>\r\n\t\t\t<li><strong>Ocular disorders</strong>: very rare cases of corneal perforation or ulceration have been reported during use. Other ocular disorders including abnormal eyelash growth, keratoconjunctivitis sicca, or keratitis have been observed, which are risk factors for corneal perforation or ulceration. Erlotinib should be interrupted or discontinued if patients present with acute or worsening ocular disorders such as eye pain</li></ul><p>Please continue to report suspected adverse reactions to erlotinib on a <a href=\"http://www.yellowcard.gov.uk\" target=\"_blank\">Yellow Card</a></p><p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON049041\" title=\"Information sent to healthcare professionals in May 2009 about the safety of medicines\">Information sent to healthcare professionals in May 2009 about the safety of medicines</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update June 2009, vol 2 issue 11: 11b.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-06-01", 
  "date_last_modified": "2010-08-18", 
  "_assets": [], 
  "_item_id": 253, 
  "summary": "", 
  "body": "Article date: June 2009\n\nErlotinib (Tarceva▼) is a treatment for patients with locally advanced or metastatic non-small-cell lung cancer, and for patients with metastatic pancreatic cancer (in combination with gemcitabine).\n\nAs part of continued intensive monitoring of this medicine, new safety information is available about the following risks:  \n  \n  * Gastrointestinal perforation: there have been reports of gastrointestinal perforation, and patients are at increased risk. Those who are receiving concomitant antiangiogenic agents, corticosteroids, non-steroidal anti-inflammatory drugs, or taxane-based chemotherapy, or who have a history of peptic ulceration or diverticular disease, are at increased risk. Erlotinib should be permanently discontinued in patients who develop gastrointestinal perforation  \n  \n  \n  * Bullous and exfoliative skin disorders: bullous, blistering, and exfoliative skin conditions have been reported, including very rare cases suggestive of Stevens-Johnson syndrome or toxic epidermal necrolysis, some of which were fatal. Erlotinib should be interrupted or discontinued if a patient develops severe bullous, blistering, or exfoliating conditions  \n  \n  \n  * Ocular disorders: very rare cases of corneal perforation or ulceration have been reported during use. Other ocular disorders including abnormal eyelash growth, keratoconjunctivitis sicca, or keratitis have been observed, which are risk factors for corneal perforation or ulceration. Erlotinib should be interrupted or discontinued if patients present with acute or worsening ocular disorders such as eye pain  \n  \nPlease continue to report suspected adverse reactions to erlotinib on a [Yellow Card](http://www.yellowcard.gov.uk)\n\nSee [Information sent to healthcare professionals in May 2009 about the safety of medicines](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON049041)\n\n \n\nArticle citation: Drug Safety Update June 2009, vol 2 issue 11: 11b.\n"
}